AU2019205328B2 - Therapeutic peptides and methods for treating autoimmune related disease - Google Patents

Therapeutic peptides and methods for treating autoimmune related disease Download PDF

Info

Publication number
AU2019205328B2
AU2019205328B2 AU2019205328A AU2019205328A AU2019205328B2 AU 2019205328 B2 AU2019205328 B2 AU 2019205328B2 AU 2019205328 A AU2019205328 A AU 2019205328A AU 2019205328 A AU2019205328 A AU 2019205328A AU 2019205328 B2 AU2019205328 B2 AU 2019205328B2
Authority
AU
Australia
Prior art keywords
peptide
seq
cells
mer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019205328A
Other languages
English (en)
Other versions
AU2019205328A1 (en
Inventor
Charles W. Henry
David Hal WAGNER JR.
Martin Glenn YUSSMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OP T LLC
Original Assignee
OP T LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/184,129 external-priority patent/US20190194290A1/en
Application filed by OP T LLC filed Critical OP T LLC
Publication of AU2019205328A1 publication Critical patent/AU2019205328A1/en
Application granted granted Critical
Publication of AU2019205328B2 publication Critical patent/AU2019205328B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2019205328A 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease Active AU2019205328B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614262P 2018-01-05 2018-01-05
US62/614,262 2018-01-05
US16/184,129 US20190194290A1 (en) 2010-10-19 2018-11-08 Methods for preventing, modulating and/or reducing cardiovascular disease
US16/184,129 2018-11-08
PCT/US2019/012425 WO2019136307A1 (en) 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease

Publications (2)

Publication Number Publication Date
AU2019205328A1 AU2019205328A1 (en) 2020-08-06
AU2019205328B2 true AU2019205328B2 (en) 2025-04-03

Family

ID=67144298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019205328A Active AU2019205328B2 (en) 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease

Country Status (9)

Country Link
EP (1) EP3735260B1 (enExample)
JP (2) JP7511242B2 (enExample)
CN (2) CN111801110B (enExample)
AU (1) AU2019205328B2 (enExample)
BR (1) BR112020013716A2 (enExample)
CA (1) CA3086193A1 (enExample)
MX (1) MX2020007081A (enExample)
SG (1) SG11202006494VA (enExample)
WO (1) WO2019136307A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012054584A2 (en) 2010-10-19 2012-04-26 The Regents Of The University Of Colorado, A Body Corporate Peptides for modulating t-cell activity and uses thereof
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US11744875B2 (en) 2019-07-12 2023-09-05 Op-T Llc Peptides and methods for treating disease
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
WO2021231898A2 (en) * 2020-05-14 2021-11-18 Op-T Llc Nanoparticle compositions and uses thereof
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN117471100B (zh) * 2022-07-22 2026-05-01 暨南大学 Th40细胞亚群在制备辅助诊断和评估系统性红斑狼疮疾病活动试剂盒中的应用
CN115807071B (zh) * 2022-09-02 2025-09-26 宁夏医科大学 检测试剂在制备2型糖尿病伴动脉粥样硬化诊断工具中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236495A1 (en) * 2010-10-19 2013-09-12 David Wagner Peptides for modulating t-cell activity and uses therof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CA2542984A1 (en) * 2003-07-07 2005-01-27 David H. Wagner Methods for predicting development of auto-immune diseases and treatment of same
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
WO2015148389A2 (en) * 2014-03-23 2015-10-01 The Regents Of The University Of Colorado Diagnosis of multiple sclerosis in human and animal subjects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130236495A1 (en) * 2010-10-19 2013-09-12 David Wagner Peptides for modulating t-cell activity and uses therof

Also Published As

Publication number Publication date
WO2019136307A1 (en) 2019-07-11
JP2021510174A (ja) 2021-04-15
EP3735260B1 (en) 2026-03-04
AU2019205328A1 (en) 2020-08-06
CN111801110A (zh) 2020-10-20
CA3086193A1 (en) 2019-07-11
EP3735260A1 (en) 2020-11-11
CN111801110B (zh) 2024-10-18
MX2020007081A (es) 2020-10-28
SG11202006494VA (en) 2020-08-28
JP7511242B2 (ja) 2024-07-05
JP2024123100A (ja) 2024-09-10
EP3735260A4 (en) 2021-12-08
CN119157997A (zh) 2024-12-20
BR112020013716A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
EP3735260B1 (en) Therapeutic peptides and methods for treating autoimmune related disease
US12428465B2 (en) Therapeutic peptides and methods for treating type 2 diabetes
US20220106381A1 (en) Cd154 peptides and methods of inhibiting cd40 interactions with cd154
US12226450B2 (en) Peptides and methods for treating disease
US20240115651A1 (en) Peptides for treating disease and reducing symptoms related to multiple sclerosis
US20200072837A1 (en) Methods for preventing, modulating and/or reducing cardiovascular disease
US20190194290A1 (en) Methods for preventing, modulating and/or reducing cardiovascular disease
EP3706799B1 (en) Peptide for preventing, modulating and/or reducing cardiovascular disease
WO2005074556A2 (en) Netrin compositions and methods of use thereof
US20260139029A1 (en) Therapeutic peptides and methods for treating autoimmune related disease
HK40095385A (en) Peptides for modulating t-cell activity and uses thereof
Jongbloed Characterisation of dendritic cell subsets in inflammatory arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)